Company news

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) news

Kyverna Therapeutics, Inc. news releases on 6ix. Latest, Sep 24, 2026: Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical…

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) news

Press releases & updates

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

The Oncology Institute Names Minh Merchant Chief Legal Officer

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024